title: Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma.
authors.forename: P
authors.initials: P
authors.lastname: Bono
authors.forename: H
authors.initials: H
authors.lastname: Elfving
authors.forename: T
authors.initials: T
authors.lastname: Utriainen
authors.forename: P
authors.initials: P
authors.lastname: Osterlund
authors.forename: T
authors.initials: T
authors.lastname: Saarto
authors.forename: T
authors.initials: T
authors.lastname: Alanko
authors.forename: H
authors.initials: H
authors.lastname: Joensuu
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001794:Blood Pressure / Q000187:drug effects; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D016001:Confidence Intervals; D018450:Disease Progression; D004334:Drug Administration Schedule; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007680:Kidney Neoplasms / Q000473:pathology*; D008875:Middle Aged; D011507:Proteinuria / Q000139:chemically induced; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab